Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger imprinted 2 (ZIM2) is a protein-coding gene belonging to the zinc finger protein family. In humans, ZIM2 and the adjacent PEG3 gene share a set of 5' exons and a common promoter, resulting in coordinated paternal expression. ZIM2 is predicted to function as a DNA-binding transcription factor and may regulate gene expression through nucleic acid interaction[1][3][7]. ZIM2 is expressed in various tissues with highest levels observed in adult testis, and modest levels in fetal kidney[4]. In terms of evolution, ZIM2 maintains a conserved genomic position near PEG3 across mammals, but its imprinting status and transcriptional regulation differ between species[1][2][6]. There is limited evidence suggesting ZIM2 is a direct therapeutic target; its association with diseases like Beckwith-Wiedemann syndrome and neonatal diabetes is likely as a candidate gene implicated by genetic studies, not as a pharmacological target[3]. No drugs, mechanisms of action, or biomarker roles are currently established for ZIM2 in the therapeutic context.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger imprinted 2 (ZIM2).